Watch this interview as TIDES TV speaks with four experts who make predictions for how the industry is going to change in the next decade and how it will look in 2030.
In March 2020, we surveyed professionals who specifically work with oligonucleotide and peptide therapeutics and small molecule drugs about the changes they expect to see over the next decade. The results reveal unique insights into where those most central to the industry think the biggest opportunities and challenges lie in the global industry, and how they expect it to look in 2030.
We have already seen a great deal of development across macromolecular drugs over the last few years alone, revealing so much potential and many lessons still to learn. How will the sector look in the next decade, and what shifts might we see throughout the biotech industry as a whole? We reached out to three experts to find out their perspective.
This whitepaper focuses on peptide cancer vaccines, although infectious disease vaccines are also touched upon. Several considerations are important such as the peptide selection, and strategies to overcome loss of MHC. Personalization opens up regulatory challenges and these are also discussed.